ChemoCentryx Inc  

(Public, NASDAQ:CCXI)   Watch this stock  
Find more results for CCXI
4.70
+0.01 (0.21%)
After Hours: 4.70 0.00 (0.00%)
Jul 29, 4:00PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.52 - 4.72
52 week 1.92 - 8.58
Open 4.70
Vol / Avg. 61,617.00/302,059.00
Mkt cap 207.72M
P/E     -
Div/yield     -
EPS -1.15
Shares 44.29M
Beta 1.48
Inst. own 57%
Aug 4, 2016
Q2 2016 ChemoCentryx Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jul 13, 2016
ChemoCentryx Inc at Cantor Fitzgerald Healthcare Conference
Jun 8, 2016
ChemoCentryx Inc at Jefferies Healthcare Conference
May 18, 2016
ChemoCentryx Inc R&D Day
May 10, 2016
Q1 2016 ChemoCentryx Inc Earnings Release
May 10, 2016
Q1 2016 ChemoCentryx Inc Earnings Call
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -84.03% -48.48%
Return on average equity -92.40% -52.24%
Employees 58 -
CDP Score - -

Address

850 Maude Ave
MOUNTAIN VIEW, CA 94043-4022
United States - Map
+1-650-2102900 (Phone)
+1-650-2102910 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

ChemoCentryx, Inc. (ChemoCentryx) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing orally-administered therapeutics to treat orphan and rare diseases, autoimmune diseases, inflammatory disorders and cancer. It targets the chemoattractant system, which is a network of molecules, including chemokine ligands and their associated receptors, as well as related chemoattractant receptors. Each of its drug candidates is a small molecule designed to target a specific chemokine or chemoattractant receptor, thereby blocking the negative inflammatory or suppressive response driven by that particular receptor, while leaving the rest of the immune system intact. The Company's pipeline comprises various programs, including orphan and rare diseases, immuno-oncology, chronic kidney disease, and other inflammatory and autoimmune diseases.

Officers and directors

Thomas J. Schall Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 55
Bio & Compensation  - Reuters
Susan M. Kanaya Chief Financial Officer, Senior Vice President - Finance, Secretary
Age: 52
Bio & Compensation  - Reuters
Petrus J. Bekker M.D., Ph.D. Senior Vice President - Clinical and Medical Affairs
Age: 54
Bio & Compensation  - Reuters
Israel F. Charo M.D., Ph.D. Senior Vice President - Research
Age: 65
Bio & Compensation  - Reuters
Markus J. Cappel Ph.D. Chief Business Officer, Treasurer
Age: 54
Bio & Compensation  - Reuters
Roger C. Lucas Ph.D. Lead Independent Director
Age: 72
Bio & Compensation  - Reuters
Thomas A. Edwards J.D, Independent Director
Age: 56
Bio & Compensation  - Reuters
Joseph M. Feczko M.D. Independent Director
Age: 66
Bio & Compensation  - Reuters
Geoffrey M. Parker Independent Director
Age: 51
Bio & Compensation  - Reuters
James L. Tyree Independent Director
Age: 62
Bio & Compensation  - Reuters